Prescribing overview
Antiseizure treatment supported by veterinary consensus.
Dogs and cats: consensus-supported seizure treatment; equine use documented in foals.
Key prescribing checks
- Never abruptly stop established therapy.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Pharmacology & pharmacokinetics
Mechanism and clinical role
Enhances inhibitory CNS activity.
Absorption, distribution, metabolism and elimination
Hepatic metabolism and renal elimination; canine autoinduction affects monitoring.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Phenobarbital
Reviewed product labeling; human restrictions require veterinary interpretation unless an animal label is specified.
Contraindications · when not to use
- Human label: barbiturate hypersensitivity, porphyria, marked liver impairment or obstructive/dyspneic respiratory disease.
Precautions & monitoring
- Dependence, respiratory depression and hepatic toxicity warrant assessment.
Species status describes the reviewed evidence, not permission to self-prescribe.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Sedation, ataxia, appetite/thirst changes; hepatic and blood abnormalities.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Veterinarian selects the individual regimen; no human doses are transferred to animals.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Identified formulation
Reviewed product labeling; human restrictions require veterinary interpretation unless an animal label is specified.
- Additive CNS depression; enzyme induction alters other drug exposure.
Monitoring
Seizure diary, serum concentrations, CBC and liver function as directed.
Client counseling
Maintain consistent administration; withdrawal requires a veterinary taper.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the dispensed container; protect from children and accidental animal ingestion.
Brands, formulations & ingredient identity
Active ingredients
Phenobarbital
Oral maintenance and monitored parenteral emergency treatment differ.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
This entry is indexed by its generic ingredient name; verify the actual manufacturer and package.
References & review status
Clinical reference updated October 26, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
